News
Public · Published
Citizens Raises Papzimeos Sales Forecast After Precigen's Q3 Topline Beat – Sees 142% Upside Potential In PGEN Stock
Precigen reported third-quarter revenue of $74.1 million, including $72.9 million in Papzimeos sales, and operating cash flow of $11.9 million. Citizens raised its PGEN price target to $12 from $11, kept its Market Outperform rating, and lifted Papzimeos sales forecasts for the fourth quarter and full-year 2027.
Published:
Updated:
What happened
Precigen reported third-quarter revenue of $74.1 million, including $72.9 million in Papzimeos sales, and operating cash flow of $11.9 million. Citizens raised its PGEN price target to $12 from $11, kept its Market Outperform rating, and lifted Papzimeos sales forecasts for the fourth quarter and full-year 2027.
Confirmed
Global impact / market context
The higher sales forecasts suggest Citizens expects Papzimeos revenue to grow beyond its earlier estimates. If sales support the company’s cash generation, Precigen may have more cash available to fund operations, though the article does not establish that the forecasts will be achieved.
Analyst inference
Precigen’s reported sales and operating cash flow provide evidence of stronger current business performance, while Citizens’ higher forecasts suggest expected growth in Papzimeos revenue. Those figures may inform investor estimates of future cash available, but they do not establish how the company or its shares will perform.
Analyst inference
What to watch
- Whether Precigen reports fourth-quarter Papzimeos sales near Citizens’ $88 million forecast, which would indicate whether the raised sales outlook is being met. Analyst inference
- Whether Precigen confirms its full-year 2027 Papzimeos sales outlook of $429 million, up from Citizens’ prior $303 million estimate. Analyst inference
- Whether operating cash flow remains positive in later quarters; sustained cash from operations could reduce the need to fund routine business costs with available cash. Analyst inference